Equities research analysts predict that Mylan N.V. (NASDAQ:MYL) will announce sales of $3.09 billion for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Mylan N.V.’s earnings. The lowest sales estimate is $3.08 billion and the highest is $3.10 billion. Mylan N.V. posted sales of $3.06 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 1%. The company is scheduled to report its next quarterly earnings report on Wednesday, November 8th.

On average, analysts expect that Mylan N.V. will report full-year sales of $3.09 billion for the current fiscal year, with estimates ranging from $11.96 billion to $12.05 billion. For the next financial year, analysts forecast that the business will post sales of $12.56 billion per share, with estimates ranging from $12.37 billion to $12.89 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Mylan N.V..

Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.18 by $0.08. The business had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.16 earnings per share.

MYL has been the topic of several research analyst reports. Barclays PLC upgraded shares of Mylan N.V. from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $47.00 to $50.00 in a report on Monday, May 22nd. BMO Capital Markets initiated coverage on shares of Mylan N.V. in a report on Monday, May 1st. They set an “outperform” rating and a $50.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Mylan N.V. in a report on Friday, June 16th. They set a “neutral” rating and a $41.00 target price on the stock. Royal Bank Of Canada set a $41.00 target price on shares of Mylan N.V. and gave the stock a “hold” rating in a report on Sunday, July 16th. Finally, Zacks Investment Research downgraded shares of Mylan N.V. from a “hold” rating to a “sell” rating in a report on Monday, May 15th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $43.43.

Mylan N.V. (NASDAQ:MYL) traded up 1.06% during mid-day trading on Friday, hitting $30.53. 3,856,561 shares of the stock traded hands. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87. The stock has a 50 day moving average price of $35.07 and a 200 day moving average price of $38.49. The firm has a market cap of $16.37 billion, a PE ratio of 24.68 and a beta of 1.27.

In related news, President Rajiv Malik sold 25,000 shares of the firm’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $40.00, for a total value of $1,000,000.00. Following the completion of the transaction, the president now directly owns 799,855 shares of the company’s stock, valued at $31,994,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Anthony Mauro sold 10,000 shares of the firm’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the transaction, the insider now directly owns 140,653 shares of the company’s stock, valued at $5,626,120. The disclosure for this sale can be found here. 0.69% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in the stock. Sentry Investment Management LLC boosted its position in Mylan N.V. by 1.1% in the second quarter. Sentry Investment Management LLC now owns 34,290 shares of the company’s stock valued at $1,331,000 after buying an additional 360 shares in the last quarter. Toronto Dominion Bank boosted its position in Mylan N.V. by 25.7% in the second quarter. Toronto Dominion Bank now owns 156,074 shares of the company’s stock valued at $6,058,000 after buying an additional 31,862 shares in the last quarter. EP Wealth Advisors LLC boosted its position in Mylan N.V. by 7.8% in the second quarter. EP Wealth Advisors LLC now owns 164,340 shares of the company’s stock valued at $6,380,000 after buying an additional 11,854 shares in the last quarter. WINTON GROUP Ltd purchased a new position in Mylan N.V. during the second quarter valued at $303,000. Finally, Gofen & Glossberg LLC IL boosted its position in Mylan N.V. by 2.4% in the second quarter. Gofen & Glossberg LLC IL now owns 15,194 shares of the company’s stock valued at $590,000 after buying an additional 360 shares in the last quarter. 71.57% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “$3.09 Billion in Sales Expected for Mylan N.V. (MYL) This Quarter” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/27/3-09-billion-in-sales-expected-for-mylan-n-v-myl-this-quarter.html.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Get a free copy of the Zacks research report on Mylan N.V. (MYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.